GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » Cyclically Adjusted PS Ratio

Recordati SpA (Recordati SpA) Cyclically Adjusted PS Ratio : 6.47 (As of Jun. 09, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Recordati SpA Cyclically Adjusted PS Ratio?

As of today (2024-06-09), Recordati SpA's current share price is $51.60. Recordati SpA's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $7.97. Recordati SpA's Cyclically Adjusted PS Ratio for today is 6.47.

The historical rank and industry rank for Recordati SpA's Cyclically Adjusted PS Ratio or its related term are showing as below:

RCDTF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 5.17   Med: 7.22   Max: 10.01
Current: 6.28

During the past years, Recordati SpA's highest Cyclically Adjusted PS Ratio was 10.01. The lowest was 5.17. And the median was 7.22.

RCDTF's Cyclically Adjusted PS Ratio is ranked worse than
86.54% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs RCDTF: 6.28

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Recordati SpA's adjusted revenue per share data for the three months ended in Mar. 2024 was $3.159. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $7.97 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Recordati SpA Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Recordati SpA's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Cyclically Adjusted PS Ratio Chart

Recordati SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.23 8.25 9.31 5.36 6.31

Recordati SpA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.31 5.83 5.84 6.31 6.48

Competitive Comparison of Recordati SpA's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Recordati SpA's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recordati SpA's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Recordati SpA's Cyclically Adjusted PS Ratio falls into.



Recordati SpA Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Recordati SpA's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=51.60/7.97
=6.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recordati SpA's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Recordati SpA's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.159/120.2000*120.2000
=3.159

Current CPI (Mar. 2024) = 120.2000.

Recordati SpA Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.593 100.093 1.913
201409 1.475 99.814 1.776
201412 1.448 99.721 1.745
201503 1.424 99.814 1.715
201506 1.418 100.279 1.700
201509 1.314 100.000 1.579
201512 1.375 99.814 1.656
201603 1.609 99.600 1.942
201606 1.536 99.900 1.848
201609 1.473 100.100 1.769
201612 1.468 100.300 1.759
201703 1.747 101.000 2.079
201706 1.660 101.100 1.974
201709 1.783 101.200 2.118
201712 1.836 101.200 2.181
201803 2.161 101.800 2.552
201806 1.841 102.400 2.161
201809 1.769 102.600 2.072
201812 1.847 102.300 2.170
201903 2.067 102.800 2.417
201906 1.947 103.100 2.270
201909 1.883 102.900 2.200
201912 2.028 102.800 2.371
202003 2.269 102.900 2.650
202006 1.782 102.900 2.082
202009 1.880 102.300 2.209
202012 2.066 102.600 2.420
202103 2.222 103.700 2.576
202106 2.192 104.200 2.529
202109 2.168 104.900 2.484
202112 2.294 106.600 2.587
202203 2.206 110.400 2.402
202206 2.394 112.500 2.558
202209 2.299 114.200 2.420
202212 2.408 119.000 2.432
202303 2.823 118.800 2.856
202306 2.553 119.700 2.564
202309 2.613 120.300 2.611
202312 2.744 119.700 2.755
202403 3.159 120.200 3.159

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Recordati SpA  (OTCPK:RCDTF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Recordati SpA Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Recordati SpA's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Recordati SpA (Recordati SpA) Business Description

Traded in Other Exchanges
Address
Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (Recordati SpA) Headlines

From GuruFocus

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

By PRNewswire PRNewswire 03-09-2020